胃がん治療市場：治療法、適応疾患、薬剤クラス別、投与経路、流通チャネル別-2025-2030年の世界予測

胃がん治療市場は、2023年に50億9,000万米ドルと評価され、2024年には55億5,000万米ドルに達すると予測され、CAGR 9.53％で成長し、2030年には96億3,000万米ドルに達すると予測されています。

胃がん治療の範囲と定義には、外科手術、化学療法、標的療法、免疫療法など、胃がんの管理や治癒を目的としたさまざまな治療アプローチが含まれます。治療の必要性は、胃がんが世界のがん関連死因の上位にランクされていることからも明らかであり、患者の転帰と生存率を改善するための効果的な治療戦略が必要とされています。胃がん治療は、治療法を個人の遺伝的体質やがんの分子プロファイルに合わせて調整し、より正確で効果的な治療レジメンを促進する個別化医療の適用において極めて重要です。最終用途の範囲には主に病院、がん研究センター、がん専門クリニックが含まれ、そこでは集学的チームが胃がんの管理にこれらの治療を展開しています。

市場情勢を左右する主要な成長要因はいくつかあるが、特に標的治療の進歩や有病率の増加が革新的な治療オプションへの需要を牽引しています。健康意識の高まりと診断技術の向上も、早期発見とタイムリーな介入を容易にするため、市場成長に寄与しています。さらに、有効性と患者のQOLの向上を約束する次世代免疫療法や併用療法レジメンの開発にも、最新の潜在的機会があります。企業は、こうした機会を引き出すため、共同研究や臨床試験に投資することが推奨されます。

しかし、市場開拓は、高い治療費、治療に対する患者の反応のばらつき、発展途上地域における高度な治療オプションへのアクセスの制限などの限界や課題に直面しています。規制上のハードルや、世界的に認められた臨床試験を実施することの複雑さが、市場拡大をさらに複雑にしています。事業成長のためには、早期発見と治療反応モニタリングのためのバイオマーカーに注目し、ドラッグデリバリー・システムを強化し、人工知能を活用して治療経路を最適化することで、技術革新を推進することができます。市場の競争は激しく、研究集約型であるため、競争力を維持し、アンメットニーズに効果的に対応するためには、継続的な技術革新と戦略的提携が必要となります。

市場力学：急速に進化する胃がん治療市場の主要市場インサイトを公開

胃がん治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 胃がん発症リスクの高い老年人口の増加
  • 座りがちで不健康なライフスタイルに伴う糖尿病患者や肥満患者の増加
  • 早期スクリーニングと早期発見の重視の高まり
• 市場抑制要因
  • 胃腸科専門医の不足と、タイムリーな診断のための検査・治療の限られた利用可能性
• 市場機会
  • 胃がんの治療と診断方法における継続的な技術進歩
• 市場の課題
  • 治療に関連する副作用

ポーターの5つの力：胃がん治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：胃がん治療市場における外部からの影響の把握

外部マクロ環境要因は、胃がん治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析胃がん治療市場における競合情勢の把握

胃がん治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス胃がん治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、胃がん治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨胃がん治療市場における成功への道筋を描く

胃がん治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 胃がん発症リスクの高い高齢者人口の増加
    • 運動不足と不健康な生活習慣により糖尿病や肥満患者が増加している
    • 早期スクリーニングと検出の重要性の高まり
  • 抑制要因
    • 消化器専門医の不足と、タイムリーな診断のためのスキャンと治療の可用性の限界
  • 機会
    • 胃がんの治療法と診断法の継続的な技術的進歩
  • 課題
    • 治療に関連する副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 胃がん治療市場治療別

• 化学療法
• 免疫療法
• 放射線治療と手術
• 標的療法

第7章 胃がん治療市場：疾患適応症別

• 胃がん・胃食道接合部がん
• 消化管間質腫瘍

第8章 胃がん治療市場薬剤クラス別

• HER2拮抗薬
• PD-1/PD-L1阻害剤
• VEGFR2拮抗薬

第9章 胃がん治療市場：投与経路別

• 注射可能
• オーラル

第10章 胃がん治療市場：流通チャネル別

• 病院薬局
• 専門薬局および小売薬局

第11章 南北アメリカの胃がん治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の胃がん治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの胃がん治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AstraZeneca PLC
• Bayer AG
• Bristol Myers Squibb Company
• Celltrion Healthcare Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline PLC
• Imugene Limited
• Jiangsu Hengrui Medicine Co., Ltd.
• Merck KGaA
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Samsung Bioepis Co., Ltd.

LIST OF FIGURES

• FIGURE 1. STOMACH CANCER TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. STOMACH CANCER TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. STOMACH CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. STOMACH CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. STOMACH CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. STOMACH CANCER TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY & SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGFR2 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY & RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 42. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 69. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 74. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 160. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 180. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 182. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 185. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 234. STOMACH CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 235. STOMACH CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Stomach Cancer Treatment Market was valued at USD 5.09 billion in 2023, expected to reach USD 5.55 billion in 2024, and is projected to grow at a CAGR of 9.53%, to USD 9.63 billion by 2030.

The scope and definition of stomach cancer treatment encompass various therapeutic approaches aimed at managing or curing gastric cancer, including surgery, chemotherapy, targeted therapy, and immunotherapy. The necessity for treatment is underscored by the global burden of stomach cancer, as it ranks among the leading causes of cancer-related deaths worldwide, necessitating effective treatment strategies to improve patient outcomes and survival rates. Stomach cancer treatment is crucial in the application of personalized medicine, where therapies are tailored to the individual's genetic makeup and the cancer's molecular profile, fostering more precise and effective treatment regimens. The end-use scope primarily includes hospitals, cancer research centers, and specialized oncology clinics, where multidisciplinary teams deploy these treatments in the management of gastric cancer.

Market insights reveal several key growth factors influencing the stomach cancer treatment landscape, notably advancements in targeted therapies and the increasing prevalence of the disease, which drives demand for innovative treatment options. Rising health awareness and improved diagnostic technologies also contribute to market growth, as they facilitate early detection and timely intervention. Moreover, the latest potential opportunities lie in developing next-generation immunotherapies and combination treatment regimens that promise to enhance efficacy and patient quality of life. Companies are recommended to invest in research collaborations and clinical trials to unlock these opportunities.

However, the market faces limitations and challenges including high treatment costs, variability in patient response to therapies, and limited access to advanced treatment options in developing regions. Regulatory hurdles and the complexity of conducting globally accepted clinical trials further complicate market expansion. For business growth, innovation can be driven by focusing on biomarkers for early detection and monitoring treatment response, enhancing drug delivery systems, and leveraging artificial intelligence to optimize treatment pathways. The nature of the market is highly competitive and research-intensive, necessitating continuous innovation and strategic partnerships to maintain a competitive edge and address unmet clinical needs effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Stomach Cancer Treatment Market

The Stomach Cancer Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising geriatric population with a high risk for the development of stomach cancer
  • Increasing cases of diabetic and obese patients coupled with sedentary & unhealthy lifestyle
  • Growing emphasis on early screening and detection
• Market Restraints
  • Dearth of gastroenterologists professionals and limited availability of scanning & treatment for timely diagnosis
• Market Opportunities
  • Continuous technological advancements in treatments and diagnostic methods for stomach cancer
• Market Challenges
  • Side effects related to treatments

Porter's Five Forces: A Strategic Tool for Navigating the Stomach Cancer Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Stomach Cancer Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Stomach Cancer Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Stomach Cancer Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Stomach Cancer Treatment Market

A detailed market share analysis in the Stomach Cancer Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Stomach Cancer Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Stomach Cancer Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Stomach Cancer Treatment Market

A strategic analysis of the Stomach Cancer Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Stomach Cancer Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., Eli Lilly and Company, F. Hoffmann La Roche Ltd., GlaxoSmithKline PLC, Imugene Limited, Jiangsu Hengrui Medicine Co., Ltd., Merck KGaA, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., and Samsung Bioepis Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Stomach Cancer Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy & Surgery, and Targeted Therapy.
• Based on Disease Indication, market is studied across Gastric Cancer/Gastroesophageal Junction Cancer and Gastrointestinal Stromal Tumors.
• Based on Drug Class, market is studied across HER2 Antagonists, PD-1/PD-L1 Inhibitors, and VEGFR2 Antagonists.
• Based on Route of Administration, market is studied across Injectable and Oral.
• Based on Distribution Channel, market is studied across Hospital Pharmacies and Specialty & Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising geriatric population with a high risk for the development of stomach cancer
    • 5.1.1.2. Increasing cases of diabetic and obese patients coupled with sedentary & unhealthy lifestyle
    • 5.1.1.3. Growing emphasis on early screening and detection
  • 5.1.2. Restraints
    • 5.1.2.1. Dearth of gastroenterologists professionals and limited availability of scanning & treatment for timely diagnosis
  • 5.1.3. Opportunities
    • 5.1.3.1. Continuous technological advancements in treatments and diagnostic methods for stomach cancer
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects related to treatments
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Stomach Cancer Treatment Market, by Treatment

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Immunotherapy
• 6.4. Radiation Therapy & Surgery
• 6.5. Targeted Therapy

7. Stomach Cancer Treatment Market, by Disease Indication

• 7.1. Introduction
• 7.2. Gastric Cancer/Gastroesophageal Junction Cancer
• 7.3. Gastrointestinal Stromal Tumors

8. Stomach Cancer Treatment Market, by Drug Class

• 8.1. Introduction
• 8.2. HER2 Antagonists
• 8.3. PD-1/PD-L1 Inhibitors
• 8.4. VEGFR2 Antagonists

9. Stomach Cancer Treatment Market, by Route of Administration

• 9.1. Introduction
• 9.2. Injectable
• 9.3. Oral

10. Stomach Cancer Treatment Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Specialty & Retail Pharmacies

11. Americas Stomach Cancer Treatment Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Stomach Cancer Treatment Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Stomach Cancer Treatment Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AstraZeneca PLC
• 2. Bayer AG
• 3. Bristol Myers Squibb Company
• 4. Celltrion Healthcare Co., Ltd.
• 5. Eli Lilly and Company
• 6. F. Hoffmann La Roche Ltd.
• 7. GlaxoSmithKline PLC
• 8. Imugene Limited
• 9. Jiangsu Hengrui Medicine Co., Ltd.
• 10. Merck KGaA
• 11. Novartis AG
• 12. Otsuka Pharmaceutical Co., Ltd.
• 13. Pfizer, Inc.
• 14. Samsung Bioepis Co., Ltd.